Tag: harbor

Kraken’s Founder Mr. Boone Smith’s extensive experience and work at U.S. Dept of Homeland Security and U.S. Customs and Border Protection adds the necessary team capabilities to assist the Company’s border security solutions effort

BOCA RATON, FL, June 12, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today it will host a live Twitter Spaces event on Monday, June 16, 2025 at 1:00 PM ET to walk investors through the company’s recent S-1 filings, its newly announced $5 billion Equity Line of Credit (ELOC), and broader public market capital strategy.

SEATTLE, June 12, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (Nasdaq: DDI) (“DoubleDown” or the “Company”) today announced the pricing of an underwritten secondary offering of 4,347,827 American Depositary Shares (the “ADSs”), each ADS representing 0.05 common share of the Company (“Common Shares”), at a public offering price of $8.50 per ADS by STIC Special Situation Diamond Limited (the “Selling Shareholder”). The Selling Shareholder has granted the underwriters a 30-day option to purchase up to 652,173 additional ADSs at the public offering price, less underwriting discounts and commissions. The offering consists entirely of the ADSs to be sold by the Selling Shareholder and will not change the number of Common Shares that are outstanding.

BOCA RATON, FL, June 12, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it has entered into a share purchase agreement (the “ELOC”) with RK Capital Management LLC (“RK Capital”).

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor^® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil^® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD).